Reuss, Joshua E https://orcid.org/0000-0002-6401-9080
Anagnostou, Valsamo
Cottrell, Tricia R
Smith, Kellie N
Verde, Franco
Zahurak, Marianna
Lanis, Mara
Murray, Joseph C
Chan, Hok Yee
McCarthy, Caroline
Wang, Daphne
White, James R
Yang, Stephen
Battafarano, Richard
Broderick, Stephen
Bush, Errol
Brock, Malcolm
Ha, Jinny
Jones, David
Merghoub, Taha
Taube, Janis
Velculescu, Victor E
Rosner, Gary
Illei, Peter
Pardoll, Drew M
Topalian, Suzanne
Naidoo, Jarushka https://orcid.org/0000-0002-3470-8686
Levy, Ben
Hellmann, Matthew D
Brahmer, Julie R
Chaft, Jamie E
Forde, Patrick M
Clinical trials referenced in this document:
Documents that mention this clinical trial
286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.286
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2020-001282
327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.327
1004 Immune checkpoint blockade unleashes mucosal associated invariant T (MAIT) cells in tumor microenvironment of NSCLC patients
https://doi.org/10.1136/jitc-2023-sitc2023.1004
293 Distinct tumor infiltrating treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.293
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
538 Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers
https://doi.org/10.1136/jitc-2022-sitc2022.0538
878 The immunomodulatory impact of chemotherapy when combined with PD-1 blockade in resectable lung cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0878
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
665 Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.665
57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
https://doi.org/10.1136/jitc-2022-sitc2022.0057
1255 Longitudinal assessment of the gut microbiome and its association with treatment response in patients with non-small cell lung cancer receiving neoadjuvant immunotherapy
https://doi.org/10.1136/jitc-2024-sitc2024.1255
Documents that mention this clinical trial
286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.286
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2020-001282
327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.327
293 Distinct tumor infiltrating treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.293
1004 Immune checkpoint blockade unleashes mucosal associated invariant T (MAIT) cells in tumor microenvironment of NSCLC patients
https://doi.org/10.1136/jitc-2023-sitc2023.1004
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
538 Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers
https://doi.org/10.1136/jitc-2022-sitc2022.0538
878 The immunomodulatory impact of chemotherapy when combined with PD-1 blockade in resectable lung cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0878
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
665 Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.665
57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
https://doi.org/10.1136/jitc-2022-sitc2022.0057
1255 Longitudinal assessment of the gut microbiome and its association with treatment response in patients with non-small cell lung cancer receiving neoadjuvant immunotherapy
https://doi.org/10.1136/jitc-2024-sitc2024.1255
Funding for this research was provided by:
Memorial Sloan Kettering Cancer Center (P30 CA008748)
Bristol-Myers Squibb (International Immuno-Oncology Network)
Conquer Cancer Foundation (90083528)
Johns Hopkins University Cancer Center (P30 CA006973)
Eastern Cooperative Oncology Group - American College of Radiology Imaging Network
Swim Across America
The Allegheny Health Network – Johns Hopkins Research Fund and the Maryland Department of Health and Mental Hygiene Cigarette Restitution Fund Program
The Commonwealth Foundation
LUNGevity Foundation
The V Foundation
Lung Cancer Foundation of America
Macmillan Foundation
National Institutes of Health (CA006973)
National Institutes of Health (CA121113)
National Institutes of Health (CA180950)
National Institutes of Health (CA233259)
National Institutes of Health (R01 CA142779)
National Institutes of Health (T32 CA009071-38)
National Institutes of Health (T32 CA193145)
Stand Up To Cancer (American Cancer Society Lung Cancer Dream Team)
Stand Up To Cancer (SU2C-AACR-DT1012)
Bloomberg-Kimmel Institute for Cancer Immunotherapy